Baseline characteristics and mortality among people in care for chronic viral hepatitis: The chronic hepatitis cohort study

Clinical Infectious Diseases

Volumn 56, Issue 1, 2013, Pages 40-50

  Moorman, Anne C ^a   Gordon, Stuart C ^b   Rupp, Loralee B ^b   Spradling, Philip R ^a   Teshale, Eyasu H ^a   Lu, Mei ^b   Nerenz, David R ^b   Nakasato, Cynthia C ^c   Boscarino, Joseph A ^d,e   Henkle, Emily M ^b   Oja Tebbe, Nancy J ^b   Xing, Jian ^a   Ward, John W ^a   Holmberg, Scott D ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c KAISER PERMANENTE   (United States)

^d GEISINGER HEALTH SYSTEM   (United States)

^e CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

cohort; HBV; HCV

Indexed keywords

ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN; CHRONIC HEPATITIS; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HOSPITALIZATION; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MORTALITY; PACIFIC ISLANDER; PATIENT CARE; PRIORITY JOURNAL;

EID: 84871245811     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis815     Document Type: Article

References (13)

1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-14.
2. Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010; 202:192-201.
3. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, & TB Prevention. Viral hepatitis surveillance, United States, 2009. Available at: http://www.cdc.gov/hepatitis/Statistics/2009 Surveillance/index.htm. Accessed 1 August 2012.
4. Mitchell AE, Colvin HM, Beasley RP. Institute of Medicine. Recommendations for the prevention and control of hepatitis B and C. Hepatol 2010; 52:729-33.
5. Pyenson B, Fitch K, Iwasaki K. Consequences of hepatitis C virus (HCV): costs of a baby boomer epidemic of liver disease. New York: Milliman, Inc, 2009.
6. Moorman AC, Holmberg SD, Marlowe SI, et al. Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV Outpatient Study (HOPS). Ann Epidemiol 1999; 9:349-57.
7. El-Kamary S, Jhaveri R, Shardell M. All-cause, liver-related, and nonliver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011; 52:150-7.
8. Ly KN, Xing J, Klevens M, Jiles RB, Ward JW, Holmberg SD. The growing burden of mortality associated with viral hepatitis in the United States, 1999-2007. Ann Intern Med 2012; 156:271-8.
9. Spradling PR, Rupp LB, Moorman AC, et al. Predictors of testing for and infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) in four United States health plans, 2006-2008. Clin Infect Dis 2012; 55:1047-55.
10. Feuerstadt P, Bunim A, Garcia H, et al. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatol 2010; 51:1137-43.
11. Cohen C, Holmberg SD, McMahon BJ, et al. Is chronic hepatitis B being undertreated in the United States? J Viral Hepatitis 2011; 18:377-83.
12. Centers for Disease Control and Prevention. Recommendations for the identification and initial care of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR 2012 (61 No): RR-4. In press, planned publication date 17 August 2012.
13. Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156:263-70.